{"id":"W4286294477","doi":"10.1200/jco.2022.40.16_suppl.4513","title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Sunitinib; Medicine; Renal cell carcinoma; Clinical endpoint; Population; Internal medicine; Hazard ratio; Oncology; Pembrolizumab; Discontinuation; Cancer; Clinical trial; Confidence interval; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003840217,0.001158328,0.002070545,0.0006011514,0.0003183876,0.0008349936,0.001023275,0.001115789,0.005487424],"category_scores_gemma":[0.0022963,0.00062815,0.002456982,0.00052024,0.0008522503,0.001042092,0.0006685344,0.002338073,0.0007362766],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001611299,"about_ca_system_score_gemma":0.001636653,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008954974,"about_ca_topic_score_gemma":0.00236959,"domain_scores_codex":[0.9983714,0.001056348,0.0001019856,0.0001845702,0.0001277195,0.0001580018],"domain_scores_gemma":[0.9984977,0.0004784623,0.0003613254,0.00009911656,0.00004536991,0.000518009],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9647852,0.009541185,0.00215209,0.0003192092,0.001218681,0.0000269737,0.00004734826,0.001059055,0.00302507,0.00007221304,0.0003973746,0.01735572],"study_design_scores_gemma":[0.5434671,0.4334009,0.01530065,0.00004498768,0.002023735,0.0001312313,0.00003705342,0.002461305,0.001792978,0.0002111489,0.001098231,0.00003081005],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950689,0.001485754,0.0004333373,0.0001737996,0.0000894572,0.001200505,0.000568639,0.00003279911,0.0009468378],"genre_scores_gemma":[0.9951627,0.0008365345,0.000822266,0.0002325176,0.0001688261,0.0008568024,0.0007308051,0.000009588596,0.001179939],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005487424,"threshold_uncertainty_score":0.02030927,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.110944628712109,"score_gpt":0.4268923143727819,"score_spread":0.3159476856606729,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}